- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in the Treatment of Multiple Sclerosis
Authors
Keywords
Multiple sclerosis, Disease-modifying treatment, Remyelination therapies, Neuroprotection therapies, Treatment approaches
Journal
NEUROLOGIC CLINICS
Volume 39, Issue 1, Pages 21-33
Publisher
Elsevier BV
Online
2020-11-07
DOI
10.1016/j.ncl.2020.09.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study
- (2020) Robert T. Naismith et al. CNS DRUGS
- Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
- (2020) Jeremy Chataway et al. LANCET NEUROLOGY
- The prevalence of MS in the United States
- (2019) Mitchell T. Wallin et al. NEUROLOGY
- Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation
- (2019) Jeffrey A. Cohen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
- (2019) Daniel Ontaneda et al. LANCET NEUROLOGY
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
- (2019) Diego Cadavid et al. LANCET NEUROLOGY
- Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
- (2019) Simon Faissner et al. NATURE REVIEWS DRUG DISCOVERY
- Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells
- (2019) Björn Neumann et al. Cell Stem Cell
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- The potential use of mesenchymal stem cells for the treatment of multiple sclerosis
- (2019) Sahar Rostami Mansoor et al. LIFE SCIENCES
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Efficacy and safety of natalizumab extended interval dosing
- (2018) Bassem I. Yamout et al. Multiple Sclerosis and Related Disorders
- Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations
- (2018) Laura E. Baldassari et al. EBioMedicine
- Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis
- (2018) Violaine K. Harris et al. EBioMedicine
- Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management
- (2018) David J Epstein et al. Open Forum Infectious Diseases
- Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab
- (2018) Jennifer Petrillo et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
- (2018) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- NEDA treatment target? No evident disease activity as an actionable outcome in practice
- (2017) Natalie E. Parks et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Clemastine fumarate for promotion of optic nerve remyelination
- (2017) Jeffrey A Cohen et al. LANCET
- Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
- (2017) Ari J Green et al. LANCET
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial
- (2016) Rhian Raftopoulos et al. LANCET NEUROLOGY
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
- (2016) Ayman Tourbah et al. Multiple Sclerosis Journal
- Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
- (2014) Jeremy Chataway et al. LANCET
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
- (2014) P. Browne et al. NEUROLOGY
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started